Related Experiment Video

Updated: Aug 19, 2026

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

The intensive care of infants with hypoplastic left heart syndrome

U Theilen1, L Shekerdemian

  • 1Intensive Care Unit, Royal Children's Hospital, Flemington Road, Parkville, Victoria 3052, Australia.

Archives of Disease in Childhood. Fetal and Neonatal Edition
|February 23, 2005
PubMed

Insights

Hypoplastic left heart syndrome was once fatal in infancy. Surgical palliation and improved peri-operative care now offer hope for affected children.

Area of Science:

  • Pediatric Cardiology
  • Congenital Heart Disease Research
  • Surgical Innovation

Background:

  • Hypoplastic left heart syndrome (HLHS) historically presented a grim prognosis, with near-universal mortality before age one.
  • Limited treatment options and understanding contributed to the fatal outcomes of HLHS.

Purpose of the Study:

  • To review the significant advancements in treating hypoplastic left heart syndrome.
  • To highlight the impact of surgical palliation and peri-operative care on HLHS outcomes.

Main Methods:

  • Review of historical data and contemporary outcomes for hypoplastic left heart syndrome.
  • Analysis of the evolution of surgical techniques and critical care for HLHS patients.

Main Results:

  • Surgical palliation has transformed HLHS from an inoperable condition to a manageable one.
  • Advances in peri-operative care have dramatically improved survival rates for infants with HLHS.

Conclusions:

  • Modern medical interventions offer a hopeful future for children diagnosed with hypoplastic left heart syndrome.
  • Continued research in surgical and critical care is vital for further improving HLHS patient outcomes.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...